Valeant meltdown costs investors billions; Ackman ups stake
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Valeant Pharma (VRX) Taps Lows Below $90/Share
October 21, 2015 1:24 PM EDTValeant Pharma (NYSE: VRX) declined 38% to session lows at around 1:20 pm on Tuesday, briefly traded under $90 per share. The massive slide follows Citron Research's fraud report earlier. So far the company hasn't responded, which might be viewed as a negative by some investors.
... More